Korinne Perry, PA
Physician Assistant · Flint, MINPI 1922525146
Payments from drug & device makers
Across 113 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$886
- Neurocrine Biosciences, Inc.$543
- Alkermes, Inc.$299
- Indivior Inc.$231
- Teva Pharmaceuticals USA, Inc.$168
- Johnson & Johnson$153
- plus $402 from 6 others
What the payments were for
- Food & beverage$2,52194%
- Education$1586%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 37 | $886 |
| Neurocrine Biosciences, Inc. | 27 | $543 |
| Alkermes, Inc. | 10 | $299 |
| Indivior Inc. | 15 | $231 |
| Teva Pharmaceuticals USA, Inc. | 4 | $168 |
| Johnson & Johnson | 3 | $153 |
| E.r. Squibb & Sons, L.L.C. | 4 | $137 |
| Sunovion Pharmaceuticals Inc. | 7 | $122 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $62 |
| AbbVie | 2 | $33 |
| Vertex | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$119
- INVEGA TRINZA$119
How this compares
$2,680 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 83 | $695,435 |
| Invega SustennaPaliperidone Palmitate | 188 | $619,638 |
| Invega TrinzaPaliperidone Palmitate | 30 | $305,977 |
| AustedoDeutetrabenazine | 16 | $157,911 |
| Abilify MaintenaAripiprazole | 45 | $131,873 |
| Clozapine | 613 | $65,396 |
| Clozapine OdtClozapine | 78 | $55,506 |
| FanaptIloperidone | 17 | $44,905 |
| Paliperidone ErPaliperidone | 140 | $40,529 |
| AristadaAripiprazole Lauroxil | 17 | $33,978 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $33,945 |
| RexultiBrexpiprazole | 22 | $33,360 |
| Chlorpromazine Hcl | 95 | $29,998 |
| Haloperidol Decanoate | 299 | $23,757 |
| VraylarCariprazine Hcl | 16 | $22,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $153 | $925,614218 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $543 | $695,43583 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $19 | $165,23367 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $168 | $157,91116 claims |
| Alkermes, Inc.Aristada, Lybalvi | $299 | $53,39529 claims |
| AbbVieVraylar | $33 | $22,05816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Flint
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.